Clinical Trial Update: A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated the safety and pharmacokinetics of MFGR1877S in patients with relapsed or refractory t(4;14)-positive multiple myeloma and has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• MFGR1877S

Snippet

Sponsor: Genentech, Inc. | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED